With Senn's expertise and infrastructure, Granules aims to scale up its innovation capabilities and diversify its portfolio into complex and next-gen therapeutics.

This >€500 million investment will feature multiple manufacturing lines capable of supporting small, medium, and large-scale peptide production with small- to large-scale Solid Phase Peptide ...